solanesyl succinate | 630393-89-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: solanesyl succinate
• 英文别名: succinic acid mono-(3,7,11,15,19,23,27,31,35-nonamethyl-hexatriaconta-2,6,10,14,18,22,26,30,34-nonaen-1-yl) ester；solanesyl hemisuccinate；solanesol hemisuccinate；4-[(2E,6E,10E,14E,18E,22E,26E,30E)-3,7,11,15,19,23,27,31,35-nonamethylhexatriaconta-2,6,10,14,18,22,26,30,34-nonaenoxy]-4-oxobutanoic acid
• CAS: 630393-89-4
• 化学式: C₄₉H₇₈O₄
• 分子量: 731.156
• InChiKey: OBOGTAKIFRGAKN-OIFJGIAKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  15.9
• 重原子数：
  53
• 可旋转键数：
  30
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  solanesyl succinate 、 loganin pentaacetate 在 4-二甲氨基吡啶 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 5.0h， 以66%的产率得到succinic acid 2-[6-(6-acetoxy-4-methoxycarbonyl-5-methyl-1,4a,5,6,7,7a-hexahydro-cyclopenta[c]pyran-1-yloxy)-3,4,5-triacetoxy-tetrahydro-pyran-2-yl]-ethyl ester 2,6,10,14,18,22,26,30,34-nonamethyl-hexatriaconta-2,6,10,14,18,22,26,30,34-nonaen-1-yl ester
  参考文献：
  名称：

  Srivastava, Shefali; Raj, Kanwal; Khare, Pratibha, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2009, vol. 48, # 2, p. 237 - 247

  摘要：

  DOI：
• 作为产物：
  描述：

  丁二酸酐 、 茄尼醇 在 4-二甲氨基吡啶 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 48.0h， 生成 solanesyl succinate
  参考文献：
  名称：

  茄尼醇修饰的紫杉醇前药及其制备方法和应 用

  摘要：

  本发明公开了一种茄尼醇修饰的紫杉醇前药及其制备方法及其应用，在此基础上制备了前药自组装纳米药物传递系统，其粒径均一（100nm左右），能够高效负载紫杉醇，制备方法简单，可重复性高；通过维生素E聚乙二醇琥珀酸酯（TPGS）对纳米制剂表面修饰长链的PEG，能够有效延长药物体内循环以及提高纳米制剂的稳定性；此外，以二硫键连接的茄尼醇‑紫杉醇前药能够在还原环境中特异性释药，有望实现紫杉醇在肿瘤部位的靶向蓄积，提高抗肿瘤效果，并降低对正常组织的毒副作用；茄尼醇为天然活性药物，具有抑制肿瘤细胞以及增加癌细胞对抗癌药物的敏感性等作用，有望增强紫杉醇的抗癌作用。

  公开号：

  CN111116521B

文献信息

• Novel class of hybrid natural products as antidiabetic agents
  作者：Kanwal Raj、Namita Misra、Geetali Pachauri、Mithelesh Sharma、Akhilesh Kumar Tamrakar、Amar Bahadur Singh、Arvind Kumar Srivastava、K. Phani Kiran、C.V. Narasimha Rao、S.R. Prubhu

  DOI：10.1080/14786410701824940

  日期：2009.1.10

  A number of O-alkylated xanthone, carbazoles and coumarins have been synthesised and screened for their in vitro anti-diabetic activity, such as glucose-6-phosphatase, glycogen phosphorylase and alpha glucosidase inhibitors. Compounds which were showing significant percentage inhibition were also tested for in vivo anti-hyperglycemic activity in sucrose loaded normal and streptozotocin (STZ)-induced diabetic rats. These compounds show 22.1, 24.4 and 26.7% and 20.8, 25.0, 20.5% lowering in sucrose loaded normal rats and STZ-induced diabetic rats at a dose of 100 mg kg-1.
• PEGylated Solanesol for Oral Delivery of Coenzyme Q₁₀
  作者：Benkai Qin、Lei Liu、Yangyang Pan、Yingchun Zhu、Xiaohe Wu、Shiyong Song、Guang Han

  DOI：10.1021/acs.jafc.7b00165

  日期：2017.4.26

  Coenzyme Q(10) (CoQ(10)) is widely used in preventive or curative treatment of cardiovascular diseases. However, CoQ(10) exhibits an extremely low solubility in aqueous medium as well as a poor oral bioavailability. Therefore, solanesyl poly(ethylene glycol) succinate (SPGS) and CoQ(10) were formulated as CoQ(10)-SPGS micelles with a high content of CoQ(10) to improve the bioavailability of CoQ(10) in rat. Findings indicate that, in the CoQ(10)-SPGS micelles, SPGS is self-assembled into stable nanosized micelles with a CoQ(10) loading capacity of more than 39%. The CoQ(10)-SPGS micelles exhibit an enhanced photostability upon exposure to simulated sunlight. In vivo experiments demonstrate that, as compared to that of the coarse suspensions of CoQa(10), there was three-fold enhancement of oral bioavailability for CoQ(10)-loaded SPGS micelles depending on varying molecular weight of SPGS. In the encapsulation of CoQ(10) by SPGS micelles, the self-assembled nano carriers with strong muco-adhesive properties lead to increases in the solubility and oral absorption of lipophilic CoQ(10) nanoparticles.